Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis.

Yu NishidaShuhei HosomiHirokazu YamagamiTomomi YukawaKoji OtaniYasuaki NagamiFumio TanakaKoichi TairaNoriko KamataTetsuya TanigawaMasatsugu ShibaKenji WatanabeToshio WatanabeKazunari TominagaYasuhiro Fujiwara

Published in: PloS one (2017)

Baseline NLR is a useful prognostic marker in patients with moderate-to-severe active UC treated with infliximab, and may contribute to appropriate use of infliximab.

Keyphrases

ulcerative colitis
early onset